BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
US |
|
L
|
LH Shopping Centers Leasehold Real Estate Investment Trust
SET:LHSC
|
TH |
|
Banco do Brasil SA
F:BZLA
|
BR |
|
B
|
B2holding ASA
OSE:B2H
|
NO |
|
Aedifica NV
XBRU:AED
|
BE |
|
V
|
Virtuix Holdings Inc
NASDAQ:VTIX
|
US |
|
SandRidge Energy Inc
NYSE:SD
|
US |
|
Medpace Holdings Inc
NASDAQ:MEDP
|
US |
|
Trimble Inc
NASDAQ:TRMB
|
US |
|
Atul Ltd
BSE:500027
|
IN |
|
SBW
KRX:102280
|
KR |
|
V
|
Vallourec SA
PAR:VK
|
FR |
|
Apollo Global Management Inc
NYSE:APO
|
US |
|
L
|
Lee & Man Paper Manufacturing Ltd
OTC:LMPMY
|
HK |
|
C
|
Canadian Tire Corporation Ltd
TSX:CTC
|
CA |
|
VGP NV
OTC:VGPBF
|
BE |
Wall St Price Targets
BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for BCRX is 21.726 USD with a low forecast of 13.13 USD and a high forecast of 33.6 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BCRX's stock price target?
Price Target
21.726
USD
According to Wall Street analysts, the average 1-year price target for BCRX is 21.726 USD with a low forecast of 13.13 USD and a high forecast of 33.6 USD.
What is the Revenue forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 31%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
10%
The compound annual growth rate for Operating Income over the next 8 years is 10%.
What is the Net Income forecast for BioCryst Pharmaceuticals Inc?
Projected CAGR
20%
The compound annual growth rate for Net Income over the next 8 years is 20%.
